NO2018037I1 - Simeprevir, eller salt derav, innbefattende natrium-simeprevir - Google Patents

Simeprevir, eller salt derav, innbefattende natrium-simeprevir

Info

Publication number: NO2018037I1
Authority: NO; Norway
Prior art keywords: simeprevir; salt; including sodium; sodium; sodium simeprevir
Prior art date: 2005-07-29

Application number

NO2018037C

Other languages

English (en)

Original Assignee

Medivir Ab

Janssen Sciences Ireland Uc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-29

Filing date

2018-10-24

Publication date

2018-10-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37067620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2018037(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-10-24 Application filed by Medivir Ab, Janssen Sciences Ireland Uc filed Critical Medivir Ab

2018-10-24 Publication of NO2018037I1 publication Critical patent/NO2018037I1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Zoology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

NO2018037C 2005-07-29 2018-10-24 Simeprevir, eller salt derav, innbefattende natrium-simeprevir NO2018037I1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP05107074		2005-07-29
EP05107417		2005-08-11
EP06101280		2006-02-03
PCT/EP2006/064820 WO2007014926A1 (en)	2005-07-29	2006-07-28	Macrocyclic inhibitors of hepatitis c virus

Publications (1)

Publication Number	Publication Date
NO2018037I1 true NO2018037I1 (no)	2018-10-24

Family

ID=37067620

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20081073A NO342393B1 (no)	2005-07-29	2008-02-29	Makrocykliske inhibitorer av hepatitt C virus
NO2018037C NO2018037I1 (no)	2005-07-29	2018-10-24	Simeprevir, eller salt derav, innbefattende natrium-simeprevir

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NO20081073A NO342393B1 (no)	2005-07-29	2008-02-29	Makrocykliske inhibitorer av hepatitt C virus

Country Status (40)

Country	Link
US (9)	US8148399B2 (no)
EP (3)	EP2322516B1 (no)
JP (1)	JP4797067B2 (no)
KR (1)	KR101059419B1 (no)
CN (3)	CN101228169B (no)
AP (1)	AP2406A (no)
AR (1)	AR055359A1 (no)
AT (1)	ATE494288T1 (no)
AU (1)	AU2006274865B2 (no)
BR (1)	BRPI0614654B1 (no)
CA (1)	CA2616580C (no)
CR (1)	CR9783A (no)
CY (3)	CY1112006T1 (no)
DE (1)	DE602006019439D1 (no)
DK (2)	DK2322516T3 (no)
EA (1)	EA015131B1 (no)
EC (1)	ECSP088150A (no)
ES (1)	ES2555230T3 (no)
GT (1)	GT200600339A (no)
HN (1)	HN2008000134A (no)
HR (2)	HRP20110237T1 (no)
HU (2)	HUE027156T2 (no)
IL (2)	IL188227A (no)
LU (1)	LU92568I2 (no)
ME (2)	ME02415B (no)
MY (1)	MY144217A (no)
NI (1)	NI200800036A (no)
NO (2)	NO342393B1 (no)
NZ (1)	NZ564550A (no)
PE (1)	PE20070211A1 (no)
PL (2)	PL2322516T3 (no)
PT (2)	PT2322516E (no)
RS (2)	RS51743B (no)
SG (1)	SG163617A1 (no)
SI (2)	SI2322516T1 (no)
SV (1)	SV2008002642A (no)
TW (1)	TWI358411B (no)
UY (1)	UY29703A1 (no)
WO (1)	WO2007014926A1 (no)
ZA (1)	ZA200800857B (no)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY140680A (en)	2002-05-20	2010-01-15	Bristol Myers Squibb Co	Hepatitis c virus inhibitors
RS51243B (sr)	2004-01-30	2010-12-31	Medivir Ab.	Inhibitori ns-3 serina hcv proteaze
BRPI0614696A2 (pt)	2005-07-29	2011-04-12	Tibotec Pharm Ltd	inibidores macrocìclicos de vìrus da hepatite c
PE20070211A1 (es)	2005-07-29	2007-05-12	Medivir Ab	Compuestos macrociclicos como inhibidores del virus de hepatitis c
ATE496042T1 (de) *	2005-07-29	2011-02-15	Tibotec Pharm Ltd	Makrocyclische inhibitoren des hepatitis-c-virus
PE20070210A1 (es) *	2005-07-29	2007-04-16	Tibotec Pharm Ltd	Compuestos macrociclicos como inhibidores del virus de hepatitis c
JP5230417B2 (ja) *	2005-07-29	2013-07-10	テイボテク・フアーマシユーチカルズ	Ｃ型肝炎ウイルスの大員環インヒビター
PE20070343A1 (es) *	2005-07-29	2007-05-12	Medivir Ab	Inhibidores macrociclicos del virus de la hepatitis c
ES2456617T3 (es) *	2005-07-29	2014-04-23	Janssen R&D Ireland	Inhibidores macrocíclicos del virus de la hepatitis C
BRPI0614242A2 (pt) *	2005-07-29	2011-03-15	Medivir Ab	inibidores macrocìclicos do vìrus da hepatite c, combinação e composição farmacêutica compreendendo os mesmos, bem como uso e processo para a preparação dos referidos inibidores
US7741281B2 (en)	2005-11-03	2010-06-22	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
CA2649043C (en)	2006-04-19	2013-09-17	Astellas Pharma Inc.	Azolecarboxamide derivative
ATE554776T1 (de) *	2006-07-07	2012-05-15	Gilead Sciences Inc	Antivirale phosphinatverbindungen
EP2049474B1 (en)	2006-07-11	2015-11-04	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
US20120220520A1 (en) *	2006-10-17	2012-08-30	Van T Klooster Gerben Albert Eleutherius	Bioavailable combinations for hcv treatment
US8343477B2 (en)	2006-11-01	2013-01-01	Bristol-Myers Squibb Company	Inhibitors of hepatitis C virus
US7772180B2 (en)	2006-11-09	2010-08-10	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8003604B2 (en)	2006-11-16	2011-08-23	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7888464B2 (en)	2006-11-16	2011-02-15	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7763584B2 (en)	2006-11-16	2010-07-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8637663B2 (en) *	2006-11-17	2014-01-28	Janssen R&D Ireland	Macrocyclic inhibitors of hepatitis C virus
PT2121674E (pt) *	2007-02-01	2010-09-03	Tibotec Pharm Ltd	Processos e intermediários para a preparação de um inibidor macrocíclico da protease do hcv
US8143402B2 (en) *	2007-02-01	2012-03-27	Tibotec Pharmaceuticals Ltd.	Polymorphic forms of a macrocyclic inhibitor of HCV
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
DK2206707T3 (da) *	2007-10-24	2014-08-11	Astellas Pharma Inc	Azolcarboxamidforbindelse eller salt deraf
US8383583B2 (en)	2007-10-26	2013-02-26	Enanta Pharmaceuticals, Inc.	Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8426360B2 (en) *	2007-11-13	2013-04-23	Enanta Pharmaceuticals, Inc.	Carbocyclic oxime hepatitis C virus serine protease inhibitors
US8263549B2 (en)	2007-11-29	2012-09-11	Enanta Pharmaceuticals, Inc.	C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
US8283309B2 (en)	2007-12-20	2012-10-09	Enanta Pharmaceuticals, Inc.	Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors
US8202996B2 (en)	2007-12-21	2012-06-19	Bristol-Myers Squibb Company	Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
BRPI0908021A2 (pt) *	2008-02-04	2015-07-21	Idenix Pharmaceuticals Inc	Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
JP5490778B2 (ja)	2008-03-20	2014-05-14	エナンタファーマシューティカルズインコーポレイテッド	Ｃ型肝炎ウイルス阻害剤としてのフッ素化大環状化合物
US8163921B2 (en)	2008-04-16	2012-04-24	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7964560B2 (en)	2008-05-29	2011-06-21	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
CN102046648A (zh)	2008-05-29	2011-05-04	百时美施贵宝公司	丙型肝炎病毒抑制剂
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
TWI454476B (zh)	2008-07-08	2014-10-01	Tibotec Pharm Ltd	用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
US8207341B2 (en)	2008-09-04	2012-06-26	Bristol-Myers Squibb Company	Process or synthesizing substituted isoquinolines
UY32099A (es)	2008-09-11	2010-04-30	Enanta Pharm Inc	Inhibidores macrocíclicos de serina proteasas de hepatitis c
CA2737376A1 (en)	2008-09-17	2010-03-25	Boehringer Ingelheim International Gmbh	Combination of hcv ns3 protease inhibitor with interferon and ribavirin
WO2010031832A2 (en) *	2008-09-18	2010-03-25	Ortho-Mcneil-Janssen Pharmaceuticals, Inc	Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
AR073603A1 (es) *	2008-09-18	2010-11-17	Ortho Mcneil Janssen Pharm	Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido
US8044087B2 (en)	2008-09-29	2011-10-25	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8563505B2 (en)	2008-09-29	2013-10-22	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8283310B2 (en)	2008-12-15	2012-10-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
JP2012513397A (ja)	2008-12-22	2012-06-14	ギリアードサイエンシーズ，インコーポレイテッド	抗ウイルス化合物
PA8855601A1 (es)	2008-12-23	2010-07-27		Forformidatos de nucleósidos
AU2009329872B2 (en)	2008-12-23	2016-07-07	Gilead Pharmasset Llc	Synthesis of purine nucleosides
BRPI0922508A8 (pt)	2008-12-23	2016-01-19	Pharmasset Inc	Análogos de nucleosídeo
KR101734507B1 (ko)	2008-12-23	2017-05-11	얀센 파마슈티칼스 인코포레이티드	Ｈｃｖ의 마크로시클릭 프로테아제 억제제를 제조하기 위한 방법 및 중간체
CN104478868A (zh) *	2009-02-27	2015-04-01	奥索-麦克尼尔-詹森药品公司	Hcv大环抑制剂的无定形盐
WO2010101967A2 (en)	2009-03-04	2010-09-10	Idenix Pharmaceuticals, Inc.	Phosphothiophene and phosphothiazole hcv polymerase inhibitors
WO2010107965A1 (en) *	2009-03-19	2010-09-23	Boehringer Ingelheim International Gmbh	Process for preparing sulfonyl quinolines
EP2417134B1 (en) *	2009-04-08	2017-05-17	Idenix Pharmaceuticals LLC.	Macrocyclic serine protease inhibitors
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
TWI598358B (zh)	2009-05-20	2017-09-11	基利法瑪席特有限責任公司	核苷磷醯胺
US8232246B2 (en)	2009-06-30	2012-07-31	Abbott Laboratories	Anti-viral compounds
CA2769652A1 (en)	2009-08-05	2011-02-10	Idenix Pharmaceuticals, Inc.	Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
CA2775697A1 (en) *	2009-09-28	2011-03-31	Intermune, Inc.	Cyclic peptide inhibitors of hepatitis c virus replication
NZ598465A (en)	2009-10-30	2013-10-25	Boehringer Ingelheim Int	Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
WO2011063076A1 (en)	2009-11-19	2011-05-26	Itherx Pharmaceuticals, Inc.	Methods of treating hepatitis c virus with oxoacetamide compounds
EP2504343A4 (en) *	2009-11-24	2013-04-17	Boehringer Ingelheim Int	HEPATITIS C INHIBITOR COMPOUNDS
TW201136942A (en)	2009-12-18	2011-11-01	Idenix Pharmaceuticals Inc	5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
EP2547645B1 (en)	2010-03-16	2018-07-04	Janssen Pharmaceuticals, Inc.	Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
US8563530B2 (en)	2010-03-31	2013-10-22	Gilead Pharmassel LLC	Purine nucleoside phosphoramidate
SI2609923T1 (sl)	2010-03-31	2017-10-30	Gilead Pharmasset Llc	Postopek za kristalizacijo (s)-izopropil 2-(((s)-(perfluorofenoksi) (fenoksi)fosforil)amino)propanoata
CA2794671C (en)	2010-03-31	2018-05-01	Gilead Pharmasset Llc	Stereoselective synthesis of phosphorus containing actives
WO2011128378A1 (en)	2010-04-13	2011-10-20	Janssen Pharmaceuticals, Inc.	Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
EP2646453A1 (en)	2010-11-30	2013-10-09	Gilead Pharmasset LLC	Compounds
PE20140039A1 (es)	2010-12-30	2014-03-01	Enanta Pharm Inc	Inhibidores de serina proteasa de hepatitis c a base de macrociclicos de fenantridina
CA2822556A1 (en)	2010-12-30	2012-07-05	Enanta Pharmaceuticals, Inc	Macrocyclic hepatitis c serine protease inhibitors
AR085352A1 (es)	2011-02-10	2013-09-25	Idenix Pharmaceuticals Inc	Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
US20120252721A1 (en)	2011-03-31	2012-10-04	Idenix Pharmaceuticals, Inc.	Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US8957203B2 (en)	2011-05-05	2015-02-17	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
US8691757B2 (en)	2011-06-15	2014-04-08	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
KR20190075142A (ko)	2011-09-16	2019-06-28	길리애드 파마셋 엘엘씨	Hcv 치료 방법
MX347855B (es) *	2011-09-16	2017-05-16	Sanofi Sa	Derivados de anilina, su preparación y su aplicación terapéutica.
AU2012311461B2 (en)	2011-09-22	2017-07-06	Janssen Pharmaceuticals, Inc.	Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
SG2014011670A (en)	2011-10-21	2014-10-30	Abbvie Inc	Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
SG2014011647A (en)	2011-10-21	2014-08-28	Abbvie Inc	Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon.
AR088568A1 (es)	2011-10-28	2014-06-18	Janssen Pharmaceuticals Inc	Proceso mejorado para preparar un compuesto intermedio del inhibidor macrociclico de la proteasa tmc 435
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
CN107964006A (zh)	2012-01-11	2018-04-27	艾伯维公司	用于制备hcv蛋白酶抑制剂的方法
CN103387509B (zh) *	2012-05-11	2016-06-08	重庆博腾制药科技股份有限公司	一种hcv蛋白酶抑制剂中间体的制备方法
UA119315C2 (uk)	2012-07-03	2019-06-10	Гіліад Фармассет Елелсі	Інгібітори вірусу гепатиту с
US20150209366A1 (en) *	2012-08-31	2015-07-30	Janssen Pharmaceuticals, Inc.	Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir
AU2013329514A1 (en)	2012-10-08	2015-04-30	Abbvie Inc.	Compounds useful for making HCV protease inhibitors
SI2909205T1 (sl)	2012-10-19	2017-02-28	Bristol-Myers Squibb Company	9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij
US9643999B2 (en)	2012-11-02	2017-05-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US9334279B2 (en)	2012-11-02	2016-05-10	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2014070964A1 (en)	2012-11-02	2014-05-08	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
WO2014070974A1 (en)	2012-11-05	2014-05-08	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
HUE047777T2 (hu)	2013-01-31	2020-05-28	Gilead Pharmasset Llc	Két vírusellenes vegyület kombinációs készítménye
US9580463B2 (en)	2013-03-07	2017-02-28	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US9617310B2 (en)	2013-03-15	2017-04-11	Gilead Sciences, Inc.	Inhibitors of hepatitis C virus
EP3650014B1 (en)	2013-08-27	2021-10-06	Gilead Pharmasset LLC	Combination formulation of two antiviral compounds
UA117375C2 (uk)	2013-09-04	2018-07-25	Медівір Аб	Інгібітори полімерази hcv
WO2015042375A1 (en)	2013-09-20	2015-03-26	Idenix Pharmaceuticals, Inc.	Hepatitis c virus inhibitors
WO2015056213A1 (en)	2013-10-17	2015-04-23	Medivir Ab	Hcv polymerase inhibitors
EP3089757A1 (en)	2014-01-03	2016-11-09	AbbVie Inc.	Solid antiviral dosage forms
CN104995189B (zh) *	2014-01-21	2017-03-29	杭州普晒医药科技有限公司	丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
US20170135990A1 (en)	2014-03-05	2017-05-18	Idenix Pharmaceuticals Llc	Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
US20170066779A1 (en)	2014-03-05	2017-03-09	Idenix Pharmaceuticals Llc	Solid forms of a flaviviridae virus inhibitor compound and salts thereof
CN105308043B (zh) *	2014-05-29	2018-01-30	杭州普晒医药科技有限公司	丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
CN105237528B (zh) *	2014-06-09	2019-06-04	深圳翰宇药业股份有限公司	Hcv抑制剂的中间体以及由其制备hcv抑制剂的方法
CN105175406B (zh) *	2014-06-09	2019-06-04	深圳翰宇药业股份有限公司	Hcv抑制剂的中间体以及由其制备hcv抑制剂的方法
MA41812A (fr)	2015-03-27	2018-01-30	Janssen Pharmaceuticals Inc	Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc
CZ2015220A3 (cs) *	2015-03-27	2016-10-05	Zentiva, K.S.	Amorfní sůl makrocyklického inhibitoru viru hepatitidy C
WO2016177625A1 (en)	2015-05-04	2016-11-10	Sandoz Ag	Amorphous simeprevir potassium
WO2017064680A1 (en) *	2015-10-16	2017-04-20	Lupin Limited	An improved process for the preparation of simeprevir sodium and intermediate thereof
CN105503851B (zh) *	2015-12-09	2017-06-23	重庆润生科技有限公司	一种烯基噻唑衍生物的制备方法
JP7129703B2 (ja)	2016-04-28	2022-09-02	エモリーユニバーシティー	アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
CN108368105B (zh) *	2016-08-12	2021-06-29	深圳市塔吉瑞生物医药有限公司	一种取代的喹啉化合物及其药物组合物及应用
JP7772687B2 (ja)	2019-07-15	2025-11-18	メディミューンリミテッド	タンパク質二量体化の三分子システム及び使用方法
US20230218644A1 (en)	2020-04-16	2023-07-13	Som Innovation Biotech, S.A.	Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2532939A1 (fr) *	1982-09-13	1984-03-16	Roussel Uclaf	Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus
CA1283906C (en)	1983-05-09	1991-05-07	Makoto Sunagawa	.beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
GB8929070D0 (en)	1989-12-22	1990-02-28	Fujisawa Pharmaceutical Co	Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
DE69331643T2 (de)	1992-12-29	2002-10-31	Abbott Laboratories, Abbott Park	Zwischenprodukte zur Herstellung retroviraler proteasehemmenden Verbindungen
IL110752A (en)	1993-09-13	2000-07-26	Abbott Lab	Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en)	1993-10-01	1996-09-24	Abbott Laboratories	Pharmaceutical composition
IL111991A (en)	1994-01-28	2000-07-26	Abbott Lab	Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en)	1995-06-29	2000-03-14	Abbott Laboratories	Method for improving pharmacokinetics
US5831108A (en) *	1995-08-03	1998-11-03	California Institute Of Technology	High metathesis activity ruthenium and osmium metal carbene complexes
US6054472A (en)	1996-04-23	2000-04-25	Vertex Pharmaceuticals, Incorporated	Inhibitors of IMPDH enzyme
US5807876A (en)	1996-04-23	1998-09-15	Vertex Pharmaceuticals Incorporated	Inhibitors of IMPDH enzyme
CN1515248A (zh)	1996-04-23	2004-07-28	��̩��˹ҩ��ɷ��޹�˾	用作肌苷-5'-一磷酸脱氢酶抑制剂的脲衍生物
EP0932617B1 (en)	1996-10-18	2002-01-16	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9623908D0 (en)	1996-11-18	1997-01-08	Hoffmann La Roche	Amino acid derivatives
DE69816280T2 (de)	1997-03-14	2004-05-27	Vertex Pharmaceuticals Inc., Cambridge	Inhibitoren des impdh-enzyms
PT1012180E (pt)	1997-08-11	2005-04-29	Boehringer Ingelheim Ca Ltd	Analogos de peptidos inibidores da hepatite c
WO1999007733A2 (en)	1997-08-11	1999-02-18	Boehringer Ingelheim (Canada) Ltd.	Hepatitis c inhibitor peptides
WO1999051613A1 (en)	1998-04-03	1999-10-14	Medivir Ab	Prodrugs of phosphorous-containing pharmaceuticals
US6038157A (en)	1998-05-28	2000-03-14	Inductotherm Corp.	Fault tolerant power supply circuit
US6639053B1 (en)	1998-06-24	2003-10-28	Tetsuya Toyoda	HCV-derived RNA polymerase gene
AR022061A1 (es)	1998-08-10	2002-09-04	Boehringer Ingelheim Ca Ltd	Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) *	1998-08-10	2001-11-27	Boehringer Ingelheim (Canada) Ltd	Hepatitis C inhibitor tri-peptides
WO2000056331A1 (en)	1999-03-19	2000-09-28	Vertex Pharmaceuticals Incorporated	Inhibitors of impdh enzyme
DE19915178A1 (de)	1999-04-03	2000-10-05	Univ Mainz Johannes Gutenberg	Hepatitis C Virus Zellkultursystem
US6608027B1 (en) *	1999-04-06	2003-08-19	Boehringer Ingelheim (Canada) Ltd	Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) *	1999-04-06	2006-01-16	Boehringer Ingelheim Ca Ltd	Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
ATE297946T1 (de)	2000-04-03	2005-07-15	Vertex Pharma	Inhibitoren von serin proteasen, speziell der hepatitis-c-virus ns3-protease
AR034127A1 (es)	2000-07-21	2004-02-04	Schering Corp	Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
US7244721B2 (en)	2000-07-21	2007-07-17	Schering Corporation	Peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (es)	2000-08-31	2003-01-13	Lilly Co Eli	Inhibidores de la proteasa peptidomimetica ref. x-14912m
MXPA03004299A (es)	2000-11-20	2004-02-12	Bristol Myers Squibb Co	Inhibidores de tripeptido de hepatitis c.
MXPA04003825A (es)	2001-10-24	2004-07-08	Vertex Pharma	Inhibidores de serina proteasa, en particular la ns3-ns4a proteasa del virus de hepatitis c, que incorpora un sistema de anillo fusionado.
US6867185B2 (en)	2001-12-20	2005-03-15	Bristol-Myers Squibb Company	Inhibitors of hepatitis C virus
MXPA04007163A (es)	2002-01-23	2004-10-29	Schering Corp	Compuestos de prolina como inhibidores de la proteasa serina ns3 para utilizarse en el tratamiento de la infeccion por el virus de la hepatitis c.
CA2369711A1 (en)	2002-01-30	2003-07-30	Boehringer Ingelheim (Canada) Ltd.	Macrocyclic peptides active against the hepatitis c virus
CA2369970A1 (en)	2002-02-01	2003-08-01	Boehringer Ingelheim (Canada) Ltd.	Hepatitis c inhibitor tri-peptides
CA2370396A1 (en)	2002-02-01	2003-08-01	Boehringer Ingelheim (Canada) Ltd.	Hepatitis c inhibitor tri-peptides
US7091184B2 (en) *	2002-02-01	2006-08-15	Boehringer Ingelheim International Gmbh	Hepatitis C inhibitor tri-peptides
US6828301B2 (en)	2002-02-07	2004-12-07	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for hepatitis C viral protease inhibitors
US7273885B2 (en)	2002-04-11	2007-09-25	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US6869964B2 (en)	2002-05-20	2005-03-22	Bristol-Myers Squibb Company	Heterocyclicsulfonamide hepatitis C virus inhibitors
EP1505945B1 (en)	2002-05-20	2008-11-05	Bristol-Myers Squibb Company	Substituted cycloalkyl p1' hepatitis c virus inhibitors
MY140680A (en)	2002-05-20	2010-01-15	Bristol Myers Squibb Co	Hepatitis c virus inhibitors
WO2004032827A2 (en)	2002-05-20	2004-04-22	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
AUPS328002A0 (en)	2002-06-28	2002-07-18	Novapharm Research (Australia) Pty Ltd	Water treatment
US20040033959A1 (en)	2002-07-19	2004-02-19	Boehringer Ingelheim Pharmaceuticals, Inc.	Pharmaceutical compositions for hepatitis C viral protease inhibitors
AU2003277891A1 (en)	2002-09-23	2004-04-08	Medivir Ab	Hcv ns-3 serine protease inhibitors
EP1408031A1 (en)	2002-10-09	2004-04-14	3 D Gene Pharma	Pyrolidine derivatives useful in treatment of hepatitis C virus infection
US20050075279A1 (en)	2002-10-25	2005-04-07	Boehringer Ingelheim International Gmbh	Macrocyclic peptides active against the hepatitis C virus
AU2003280239B2 (en)	2002-10-29	2009-03-12	Boehringer Ingelheim International Gmbh	Inhibitor-resistant HCV NS3 protease
US20050159345A1 (en)	2002-10-29	2005-07-21	Boehringer Ingelheim International Gmbh	Composition for the treatment of infection by Flaviviridae viruses
KR100940619B1 (ko)	2003-02-07	2010-02-05	이난타 파마슈티칼스, 인코포레이티드	마크로사이클릭 씨형 간염 세린 단백효소 억제제
JP4682140B2 (ja)	2003-03-05	2011-05-11	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃ型肝炎インヒビターペプチド類縁体
EP1601685A1 (en)	2003-03-05	2005-12-07	Boehringer Ingelheim International GmbH	Hepatitis c inhibiting compounds
UY28240A1 (es) *	2003-03-27	2004-11-08	Boehringer Ingelheim Pharma	Fases cristalinas de un potente inhibidor de la hcv
US7157424B2 (en)	2003-04-02	2007-01-02	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for hepatitis C viral protease inhibitors
US7148347B2 (en)	2003-04-10	2006-12-12	Boehringer Ingelheim International Gmbh	Process for preparing macrocyclic compounds
TW200510391A (en)	2003-04-11	2005-03-16	Vertex Pharma	Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
ATE422895T1 (de)	2003-04-16	2009-03-15	Bristol Myers Squibb Co	Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
PL1615613T3 (pl)	2003-04-18	2010-04-30	Enanta Pharm Inc	Chinoksalinylowe makrocykliczne inhibitory proteazy serynowej zapalenia wątroby typu C
CL2004001161A1 (es)	2003-05-21	2005-04-08	Boehringer Ingelheim Int	Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
WO2004113365A2 (en)	2003-06-05	2004-12-29	Enanta Pharmaceuticals, Inc.	Hepatitis c serine protease tri-peptide inhibitors
US7125845B2 (en) *	2003-07-03	2006-10-24	Enanta Pharmaceuticals, Inc.	Aza-peptide macrocyclic hepatitis C serine protease inhibitors
AU2004274051A1 (en) *	2003-09-22	2005-03-31	Boehringer Ingelheim International Gmbh	Macrocyclic peptides active against the hepatitis C virus
DE10344793A1 (de)	2003-09-26	2005-04-14	Rieter Automatik Gmbh	Vorrichtung zum Granulieren thermoplastischer Kunststoffe
RS51243B (sr) *	2004-01-30	2010-12-31	Medivir Ab.	Inhibitori ns-3 serina hcv proteaze
SE0400199D0 (sv) *	2004-01-30	2004-01-30	Medivir Ab	HCV Protease inhbitors
WO2006033878A1 (en) *	2004-09-17	2006-03-30	Boehringer Ingelheim International, Gmbh	Process for preparing macrocyclic hcv protease inhibitors
BRPI0614242A2 (pt)	2005-07-29	2011-03-15	Medivir Ab	inibidores macrocìclicos do vìrus da hepatite c, combinação e composição farmacêutica compreendendo os mesmos, bem como uso e processo para a preparação dos referidos inibidores
BRPI0614696A2 (pt) *	2005-07-29	2011-04-12	Tibotec Pharm Ltd	inibidores macrocìclicos de vìrus da hepatite c
ATE496042T1 (de) *	2005-07-29	2011-02-15	Tibotec Pharm Ltd	Makrocyclische inhibitoren des hepatitis-c-virus
JO2768B1 (en)	2005-07-29	2014-03-15	تيبوتيك فارماسيوتيكالز ليمتد	Large cyclic inhibitors of hepatitis C virus
PE20070210A1 (es) *	2005-07-29	2007-04-16	Tibotec Pharm Ltd	Compuestos macrociclicos como inhibidores del virus de hepatitis c
DK1912996T3 (da)	2005-07-29	2012-09-17	Janssen R & D Ireland	Makrocykliske inhibitorer af hepatitis C-virus
PE20070343A1 (es) *	2005-07-29	2007-05-12	Medivir Ab	Inhibidores macrociclicos del virus de la hepatitis c
BRPI0613933A2 (pt) *	2005-07-29	2011-02-22	Medivir Ab	inibidores macrocìlicos do vìrus da hepatite c
ES2456617T3 (es)	2005-07-29	2014-04-23	Janssen R&D Ireland	Inhibidores macrocíclicos del virus de la hepatitis C
PE20070211A1 (es)	2005-07-29	2007-05-12	Medivir Ab	Compuestos macrociclicos como inhibidores del virus de hepatitis c
JP5230417B2 (ja) *	2005-07-29	2013-07-10	テイボテク・フアーマシユーチカルズ	Ｃ型肝炎ウイルスの大員環インヒビター
US8143402B2 (en)	2007-02-01	2012-03-27	Tibotec Pharmaceuticals Ltd.	Polymorphic forms of a macrocyclic inhibitor of HCV
WO2011128378A1 (en)	2010-04-13	2011-10-20	Janssen Pharmaceuticals, Inc.	Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
US8402690B2 (en)	2010-09-09	2013-03-26	Sterling International Inc.	Bedbug trap

2006
- 2006-07-26 PE PE2006000910A patent/PE20070211A1/es active IP Right Grant
- 2006-07-28 US US11/632,102 patent/US8148399B2/en not_active Expired - Fee Related
- 2006-07-28 EP EP10187197.8A patent/EP2322516B1/en active Active
- 2006-07-28 SI SI200632004T patent/SI2322516T1/sl unknown
- 2006-07-28 EP EP06778071A patent/EP1912999B1/en active Active
- 2006-07-28 CN CN2006800269505A patent/CN101228169B/zh not_active Expired - Fee Related
- 2006-07-28 JP JP2008523382A patent/JP4797067B2/ja not_active Expired - Fee Related
- 2006-07-28 EA EA200800476A patent/EA015131B1/ru not_active IP Right Cessation
- 2006-07-28 BR BRPI0614654-6A patent/BRPI0614654B1/pt not_active IP Right Cessation
- 2006-07-28 MY MYPI20063669A patent/MY144217A/en unknown
- 2006-07-28 HR HR20110237T patent/HRP20110237T1/hr unknown
- 2006-07-28 PT PT101871978T patent/PT2322516E/pt unknown
- 2006-07-28 SI SI200630969T patent/SI1912999T1/sl unknown
- 2006-07-28 ES ES10187197.8T patent/ES2555230T3/es active Active
- 2006-07-28 RS RS20110145A patent/RS51743B/sr unknown
- 2006-07-28 CA CA002616580A patent/CA2616580C/en not_active Expired - Fee Related
- 2006-07-28 AP AP2008004301A patent/AP2406A/xx active
- 2006-07-28 KR KR1020087003598A patent/KR101059419B1/ko not_active Expired - Fee Related
- 2006-07-28 PT PT06778071T patent/PT1912999E/pt unknown
- 2006-07-28 ME MEP-2015-208A patent/ME02415B/me unknown
- 2006-07-28 WO PCT/EP2006/064820 patent/WO2007014926A1/en not_active Ceased
- 2006-07-28 AU AU2006274865A patent/AU2006274865B2/en not_active Ceased
- 2006-07-28 HU HUE10187197A patent/HUE027156T2/en unknown
- 2006-07-28 PL PL10187197T patent/PL2322516T3/pl unknown
- 2006-07-28 DE DE602006019439T patent/DE602006019439D1/de active Active
- 2006-07-28 AR ARP060103304A patent/AR055359A1/es not_active Application Discontinuation
- 2006-07-28 GT GT200600339A patent/GT200600339A/es unknown
- 2006-07-28 PL PL06778071T patent/PL1912999T3/pl unknown
- 2006-07-28 CN CN201210389139.0A patent/CN103030636B/zh not_active Expired - Fee Related
- 2006-07-28 AT AT06778071T patent/ATE494288T1/de active
- 2006-07-28 DK DK10187197.8T patent/DK2322516T3/en active
- 2006-07-28 EP EP15158049.5A patent/EP2937339A1/en not_active Withdrawn
- 2006-07-28 NZ NZ564550A patent/NZ564550A/en not_active IP Right Cessation
- 2006-07-28 DK DK06778071.8T patent/DK1912999T3/da active
- 2006-07-28 ME MEP-2011-58A patent/ME01231B/me unknown
- 2006-07-28 SG SG201005140-7A patent/SG163617A1/en unknown
- 2006-07-28 RS RS20150857A patent/RS54473B1/sr unknown
- 2006-07-28 UY UY29703A patent/UY29703A1/es not_active Application Discontinuation
- 2006-07-28 TW TW095127587A patent/TWI358411B/zh not_active IP Right Cessation
- 2006-07-28 CN CN201210047344.9A patent/CN102627639B/zh not_active Expired - Fee Related
- 2006-07-29 SV SV2006002642A patent/SV2008002642A/es unknown
2007
- 2007-12-18 IL IL188227A patent/IL188227A/en not_active IP Right Cessation
2008
- 2008-01-28 HN HN2008000134A patent/HN2008000134A/es unknown
- 2008-01-28 ZA ZA2008/00857A patent/ZA200800857B/en unknown
- 2008-01-28 EC EC2008008150A patent/ECSP088150A/es unknown
- 2008-01-29 NI NI200800036A patent/NI200800036A/es unknown
- 2008-02-29 CR CR9783A patent/CR9783A/es unknown
- 2008-02-29 NO NO20081073A patent/NO342393B1/no not_active IP Right Cessation
2011
- 2011-04-05 CY CY20111100360T patent/CY1112006T1/el unknown
- 2011-08-03 US US13/197,226 patent/US8153800B2/en not_active Expired - Fee Related
2012
- 2012-03-06 US US13/412,997 patent/US8349869B2/en not_active Expired - Fee Related
- 2012-11-28 US US13/687,037 patent/US8741926B2/en not_active Expired - Fee Related
2013
- 2013-03-15 US US13/832,166 patent/US8754106B2/en not_active Expired - Fee Related
2014
- 2014-05-23 US US14/285,854 patent/US9040562B2/en active Active
- 2014-10-07 HU HUS1400054C patent/HUS1400054I1/hu unknown
- 2014-10-07 CY CY2014044C patent/CY2014044I2/el unknown
- 2014-10-07 LU LU92568C patent/LU92568I2/xx unknown
2015
- 2015-04-13 US US14/684,649 patent/US9353103B2/en not_active Expired - Fee Related
- 2015-07-30 IL IL240244A patent/IL240244A0/en unknown
- 2015-12-04 HR HRP20151326TT patent/HRP20151326T1/hr unknown
- 2015-12-21 CY CY20151101162T patent/CY1117392T1/el unknown
2016
- 2016-04-25 US US15/137,997 patent/US9623022B2/en not_active Expired - Fee Related
2017
- 2017-03-09 US US15/454,911 patent/US9856265B2/en not_active Expired - Fee Related
2018
- 2018-10-24 NO NO2018037C patent/NO2018037I1/no unknown

Also Published As

Publication number	Publication date
HUE027156T2 (en)	2016-08-29
US20110295012A1 (en)	2011-12-01
PL1912999T3 (pl)	2011-06-30
DK1912999T3 (da)	2011-04-18
IL188227A (en)	2015-08-31
EP1912999B1 (en)	2011-01-05
CN102627639A (zh)	2012-08-08
CN101228169A (zh)	2008-07-23
US20140255347A1 (en)	2014-09-11
NO20081073L (no)	2008-04-28
BRPI0614654A2 (pt)	2011-04-12
TWI358411B (en)	2012-02-21
US8741926B2 (en)	2014-06-03
MY144217A (en)	2011-08-15
US9623022B2 (en)	2017-04-18
US20130217725A1 (en)	2013-08-22
EP2937339A1 (en)	2015-10-28
DE602006019439D1 (de)	2011-02-17
TW200745117A (en)	2007-12-16
EP2322516A1 (en)	2011-05-18
SV2008002642A (es)	2008-08-29
RS54473B1 (sr)	2016-06-30
US20090281140A1 (en)	2009-11-12
AU2006274865A1 (en)	2007-02-08
JP2009502889A (ja)	2009-01-29
US8153800B2 (en)	2012-04-10
HRP20110237T1 (hr)	2011-05-31
EP2322516B1 (en)	2015-09-23
ME01231B (me)	2013-06-20
NZ564550A (en)	2010-06-25
IL188227A0 (en)	2008-03-20
LU92568I2 (fr)	2015-10-29
DK2322516T3 (en)	2015-12-14
US9040562B2 (en)	2015-05-26
US8148399B2 (en)	2012-04-03
ME02415B (me)	2016-09-20
PL2322516T3 (pl)	2016-03-31
AR055359A1 (es)	2007-08-22
PE20070211A1 (es)	2007-05-12
UY29703A1 (es)	2007-05-31
KR20080042084A (ko)	2008-05-14
US8349869B2 (en)	2013-01-08
GT200600339A (es)	2007-09-05
WO2007014926A1 (en)	2007-02-08
US9856265B2 (en)	2018-01-02
US20160235737A1 (en)	2016-08-18
US20120171157A1 (en)	2012-07-05
CY2014044I1 (el)	2016-04-13
CY1117392T1 (el)	2017-04-26
HN2008000134A (es)	2010-11-03
US20150218153A1 (en)	2015-08-06
CN103030636A (zh)	2013-04-10
HUS1400054I1 (hu)	2016-09-28
NI200800036A (es)	2016-02-23
HRP20151326T1 (hr)	2016-01-29
EA200800476A1 (ru)	2008-08-29
ECSP088150A (es)	2008-02-20
SI1912999T1 (sl)	2011-05-31
ES2555230T3 (es)	2015-12-29
PT1912999E (pt)	2011-03-31
HK1183872A1 (zh)	2014-01-10
CN101228169B (zh)	2013-03-13
EA015131B1 (ru)	2011-06-30
AP2406A (en)	2012-05-02
CY2014044I2 (el)	2016-04-13
JP4797067B2 (ja)	2011-10-19
US20170226111A1 (en)	2017-08-10
PT2322516E (pt)	2016-01-15
AU2006274865B2 (en)	2010-06-24
SI2322516T1 (sl)	2016-02-29
BRPI0614654B1 (pt)	2019-03-12
IL240244A0 (en)	2015-09-24
SG163617A1 (en)	2010-08-30
CA2616580A1 (en)	2007-02-08
CR9783A (es)	2008-09-09
HK1116771A1 (en)	2009-01-02
US20130089520A1 (en)	2013-04-11
US8754106B2 (en)	2014-06-17
NO342393B1 (no)	2018-05-14
ZA200800857B (en)	2014-07-30
KR101059419B1 (ko)	2011-08-29
US9353103B2 (en)	2016-05-31
CY1112006T1 (el)	2015-11-04
CN102627639B (zh)	2017-04-12
CA2616580C (en)	2009-10-06
ATE494288T1 (de)	2011-01-15
RS51743B (sr)	2011-10-31
EP1912999A1 (en)	2008-04-23
CN103030636B (zh)	2016-03-02

Publication	Publication Date	Title
NO2018037I1 (no)	2018-10-24	Simeprevir, eller salt derav, innbefattende natrium-simeprevir
FIC20210018I1 (fi)	2021-06-14	Cenobamat eller ett farmaceutiskt salt därav
FIC20253005I1 (fi)	2025-07-31	Seladelpaarin L-lysiinisuola, erityisesti seladelpaari-L-lysiinidihydraatti
NO2018027I1 (no)	2018-08-27	[18F]FACBC eller fluciklovin
NL300885I2 (nl)	2022-02-24	Irinotecansucrosofaatzout
DK2206707T3 (da)	2014-08-11	Azolcarboxamidforbindelse eller salt deraf
NL1031741A1 (nl)	2006-11-07	Purinederivaten.
DK1928882T3 (da)	2013-11-04	(s)-n-methylnaltrexon
DK1889198T3 (da)	2015-02-09	Farma-informatiksystem
DE602006012117D1 (de)	2010-03-25	Gewebe-wiederherstellungssystem
DK2042480T3 (da)	2013-05-27	Aminoindan-derivat eller salt deraf
PL1859237T3 (pl)	2014-09-30	Układ wagowy
ATE537171T1 (de)	2011-12-15	Aryl-isoxazol-4-yl-imidazoä1,5-aüpyridin-deriva e
DE602006010581D1 (de)	2009-12-31	4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
DE602005004015D1 (de)	2008-02-07	Zerkleinerer
ATE485294T1 (de)	2010-11-15	Azaindol-2-carboxamid-derivate
ATE527255T1 (de)	2011-10-15	Aryl-isoxazol-4-yl-imidazol-derivate
DK1864976T3 (da)	2012-10-22	Propan-1,3-dion-derivat eller salt deraf
DK1971588T3 (da)	2012-10-22	Tiglien-3-onderivater
NO20082650L (no)	2008-06-06	Benzenderivat eller salt derav
FI20080436L (fi)	2008-09-12	Terä
ITMI20050051A1 (it)	2006-07-19	Fotodiodio organico di poli-9,9-diottil-fluorene
DE502006007704D1 (de)	2010-09-30	Fördereinheit
ATE541837T1 (de)	2012-02-15	Oxaphenanthren-derivate
DE502006006792D1 (de)	2010-06-02	Fördereinheit